SG160329A1 - Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - Google Patents

Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Info

Publication number
SG160329A1
SG160329A1 SG201001049-4A SG2010010494A SG160329A1 SG 160329 A1 SG160329 A1 SG 160329A1 SG 2010010494 A SG2010010494 A SG 2010010494A SG 160329 A1 SG160329 A1 SG 160329A1
Authority
SG
Singapore
Prior art keywords
meningitis
sepsis
proteins
nucleic acids
escherichia coli
Prior art date
Application number
SG201001049-4A
Other languages
English (en)
Inventor
Vega Masignani
Moriel Danilo Gomes
Scorza Francesco Berlanda
Nathalie Norais
Maria Rita Fontana
Mariagrazia Pizza
Laura Serino
Herve Tettelin
Original Assignee
Novartis Vaccines & Diagnostic
Craig J Venter Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Craig J Venter Inst Inc filed Critical Novartis Vaccines & Diagnostic
Publication of SG160329A1 publication Critical patent/SG160329A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201001049-4A 2005-02-18 2006-02-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli SG160329A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65463205P 2005-02-18 2005-02-18
US71272005P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
SG160329A1 true SG160329A1 (en) 2010-04-29

Family

ID=36917149

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001049-4A SG160329A1 (en) 2005-02-18 2006-02-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Country Status (18)

Country Link
US (4) US8758764B2 (xx)
EP (2) EP2351772B1 (xx)
JP (2) JP2008529558A (xx)
AU (1) AU2006214064B2 (xx)
CA (1) CA2601924A1 (xx)
CY (2) CY1117732T1 (xx)
DK (2) DK1858920T3 (xx)
ES (2) ES2595363T3 (xx)
HU (2) HUE030881T2 (xx)
IL (2) IL185359A0 (xx)
LT (1) LT2351772T (xx)
MX (1) MX306302B (xx)
NZ (3) NZ597685A (xx)
PL (2) PL1858920T3 (xx)
PT (1) PT2351772T (xx)
SG (1) SG160329A1 (xx)
SI (2) SI2351772T1 (xx)
WO (1) WO2006089264A2 (xx)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221761B1 (en) * 1999-02-26 2012-07-17 Novartis Ag Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs
MXPA03003690A (es) * 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
ITMI20081249A1 (it) * 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
JP5332237B2 (ja) * 2008-03-06 2013-11-06 味の素株式会社 Ｌ−システイン生産菌及びｌ−システインの製造法
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
CN102159242A (zh) 2008-09-18 2011-08-17 诺华有限公司 疫苗佐剂组合
WO2010124085A2 (en) * 2009-04-23 2010-10-28 Cornell University Compositions and methods for preventing and treating uterine disease
US9119802B2 (en) 2009-05-06 2015-09-01 Cornell University E. coli LpfA antigen for prevention and treatment of infectious diseases
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
SG177533A1 (en) * 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
EP2277989A1 (en) 2009-07-24 2011-01-26 Technische Universiteit Delft Fermentative glycerol-free ethanol production
JP2013503148A (ja) * 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
ATE557035T1 (de) * 2009-09-10 2012-05-15 Univ Berlin Freie Identifizierung und charakterisierung eines neuartigen aviären pathogenen e. coli (apec) fimbrien-adhäsins
US20120301434A1 (en) * 2009-10-02 2012-11-29 Oslo Universitetssykehus Hf Antibacterial polypeptides and use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
DK2509961T3 (en) 2009-12-11 2016-05-17 Autifony Therapeutics Ltd Imidazolidinedione derivatives
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
SI4005592T1 (sl) 2010-07-06 2023-03-31 Glaxosmithkline Biologicals S.A. Virionom podobni dostavni delci za samopodvojene molekule RNA
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
WO2012031046A2 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
ES2938866T3 (es) 2010-08-31 2023-04-17 Glaxosmithkline Biologicals Sa Liposomas pegilados para la administración de ARN que codifica para inmunógeno
CN103313725B (zh) 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
CA2810971C (en) * 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
ES2716243T3 (es) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
DK2750707T3 (en) 2011-08-31 2019-02-11 Glaxosmithkline Biologicals Sa PEGYLED LIPOSOMES FOR DELIVERING IMMUNOGEN-CODING RNA
WO2013038385A2 (en) 2011-09-14 2013-03-21 Novartis Ag Escherichia coli vaccine combination
KR101359844B1 (ko) * 2012-01-06 2014-02-25 씨제이제일제당 (주) 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법
JP5961635B2 (ja) * 2012-01-18 2016-08-02 三井化学株式会社 １、５−ペンタメチレンジアミンの製造方法
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
ES2597755T3 (es) 2012-03-07 2017-01-20 Glaxosmithkline Biologicals Sa Sales de arginina de un agonista de TLR7
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
CN104812773B (zh) * 2012-07-20 2018-04-06 庆熙大学校产学协力团 表位标记用抗体、杂交瘤细胞株以及其用途
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
MX2015004844A (es) * 2012-10-17 2015-11-16 Enterome Firmas geneticas de trastornos inflamatorios que se relacionan con el higado.
WO2014078270A1 (en) * 2012-11-13 2014-05-22 The General Hospital Corporation In vitro assays for detecting salmonella enterica serotype typhi
WO2014102694A1 (en) 2012-12-24 2014-07-03 Novartis Ag Novel mucinase for use in therapy or prophylaxis
BR112015021791B1 (pt) 2013-03-08 2022-08-30 Novartis Ag Compostos de lipídio catiônico e composições de lipídios e farmacêuticas
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN110540991B (zh) 2013-03-15 2023-10-24 通用医疗公司 使用截短的引导RNA(tru-gRNA)提高RNA引导的基因组编辑的特异性
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
KR101525663B1 (ko) 2013-05-10 2015-06-04 씨제이제일제당 (주) 신규 ｏ-포스포세린 배출 단백질 및 이를 이용한 ｏ-포스포세린의 생산방법
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
KR20150018227A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 외인성 푸마라아제 유전자를 포함하는 코리네박테리움 및 이를 이용한 c4 디카르복실산의 생산 방법
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3872066A1 (en) 2013-12-19 2021-09-01 Novartis AG Lipids and lipid compositions for the delivery of active agents
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US10624934B2 (en) * 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
CA2941694A1 (en) 2014-03-06 2015-09-11 Research Institute At Nationwide Children's Hospital Probiotic formulations and methods for use
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016037053A1 (en) 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN107771214B (zh) * 2015-04-07 2022-01-18 代谢探索者公司 用于具有增加的2,4-二羟基丁酸外排物的优化的2,4-二羟基丁酸产生的修饰的微生物
US20160317615A1 (en) * 2015-05-01 2016-11-03 Jose Javier Lopez GONZALEZ T cell modulator
US11209972B2 (en) 2015-09-02 2021-12-28 D&M Holdings, Inc. Combined tablet screen drag-and-drop interface
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2017086329A1 (ja) * 2015-11-16 2017-05-26 国立大学法人熊本大学 細胞の再プログラミングを誘導する組成物、及び該組成物を用いた多能性細胞の製造方法
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
CA3011901A1 (en) 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
EP3416667A4 (en) * 2016-02-17 2020-02-26 Pepticom Ltd PEPTIDAGONISTS AND ANTAGONISTS OF TLR4 ACTIVATION
WO2017160779A2 (en) * 2016-03-14 2017-09-21 The Translational Genomics Research Institute Methods and kits to identify klebsiella strains
EP3430156A1 (en) * 2016-03-16 2019-01-23 DSM IP Assets B.V. Microbial production of nicotinic acid riboside
ES2869300T3 (es) * 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
CN112601821A (zh) * 2018-07-09 2021-04-02 科德克希思公司 工程化磷酸戊糖变位酶变体酶
AU2019355194A1 (en) * 2018-10-05 2021-04-22 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
KR101991207B1 (ko) 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101996767B1 (ko) * 2018-11-29 2019-07-04 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101991206B1 (ko) * 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
EP3893856A4 (en) * 2018-12-10 2022-10-05 Flagship Pioneering Innovations VI, LLC ACHROMOSOMAL DYNAMIC ACTIVE SYSTEMS
EP3984546A4 (en) * 2019-05-15 2023-09-27 Universidad de Granada GENE THERAPY USING HOKD AND LDRB GENES FOR CANCER TREATMENT
CN114008070A (zh) * 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
CN110441284B (zh) * 2019-07-23 2022-02-15 海南大学 一种可用于痕量检测的表面增强拉曼散射芯片的制备方法及所得产品和应用
US20230041211A1 (en) * 2019-12-20 2023-02-09 Basf Se Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
CN111778224B (zh) * 2020-07-20 2021-06-01 成都薇合生物科技有限公司 尿酸酶或其同源酶及其应用
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
CN112391331B (zh) * 2020-11-12 2022-09-27 江南大学 一种过表达GatA基因的重组大肠杆菌及其应用
CN114137209B (zh) * 2021-02-01 2024-03-01 中国水产科学研究院黄海水产研究所 一种快速检测牡蛎疱疹病毒抗原的免疫荧光检测试纸条及应用
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
CA3215752A1 (en) * 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023022788A1 (en) * 2021-08-18 2023-02-23 The Regents Of The University Of California Methods and compositions for determining risk of autism spectrum disorders
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
CN114107413B (zh) * 2021-11-03 2023-10-20 江苏香地化学有限公司 一种酶催化胞嘧啶生产胞苷的方法及应用
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023122632A1 (en) * 2021-12-21 2023-06-29 Sri International Dual targeting for cell-specific delivery to the central nervous system
CN114522230A (zh) * 2022-01-11 2022-05-24 上海市伤骨科研究所 一种蓝光和对苯醌联合杀菌方法
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用
WO2023245129A2 (en) * 2022-06-15 2023-12-21 Quantum-Si Incorporated Directed protein evolution
WO2024073730A2 (en) * 2022-09-29 2024-04-04 The University Of Chicago Methods and systems for rna sequencing and analysis
WO2024083912A1 (en) 2022-10-19 2024-04-25 Glyprovac Aps Glycosylated yghj polypeptides from uropathogenic e. coli
CN118086235A (zh) * 2022-11-28 2024-05-28 宁波酶赛生物工程有限公司 一种合成d-泛解酸的酶催化剂和方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
SG70625A1 (en) 1991-03-01 2000-02-22 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997004110A1 (en) 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
AU7301698A (en) * 1996-11-22 1998-06-10 Human Genome Sciences, Inc. Thermostable polymerases having altered fidelity
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
BR9814878A (pt) 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69924262T3 (de) 1998-08-14 2009-07-23 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
WO2002016439A2 (en) 2000-03-07 2002-02-28 Hyseq, Inc. Novel nucleic acids and polypeptides
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
DE60012711T2 (de) 1999-03-26 2005-08-18 Vical, Inc., San Diego Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
WO2000068253A1 (en) 1999-05-05 2000-11-16 Sterrenbeld Biotechnologie North America, Inc. Dna promoter sequence for gene expression
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
JP2003509452A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ポリオキシエチレンアルキルエーテル又はエステル及び少なくとも一つのノニオン界面活性剤を含有するアジュバント
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
CA2402602A1 (en) * 2000-03-10 2001-09-13 Edouard Bingen Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1297005B1 (en) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
EP1650203B1 (en) 2000-09-11 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Process of preparation of benzimidazol-2-yl quinolinone derivatives
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
WO2002059320A2 (en) 2000-10-19 2002-08-01 Wisconsin Alumni Research Foundation Dna sequences of escherichia coli cft073
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
EP1372706B1 (en) 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
DE60234376D1 (de) 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030165870A1 (en) * 2002-03-01 2003-09-04 Blattner Frederick R. Novel sequences of E. coli CFT073
EP1342784A1 (en) * 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
CA2496246A1 (en) 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
WO2004032958A1 (en) 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20040209370A1 (en) 2002-12-19 2004-10-21 Wonchul Suh Method for chromosomal engineering
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP1441036A1 (en) 2003-01-27 2004-07-28 Université de Nantes Method for the identification and isolation of strong bacterial promoters
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
JP4049045B2 (ja) 2003-07-28 2008-02-20 トヨタ自動車株式会社 蓄熱装置付きエンジンシステム
KR101178776B1 (ko) * 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso

Also Published As

Publication number Publication date
EP2351772B1 (en) 2016-07-13
SI1858920T1 (sl) 2016-07-29
PL2351772T3 (pl) 2017-01-31
NZ597685A (en) 2013-12-20
EP1858920A2 (en) 2007-11-28
WO2006089264A2 (en) 2006-08-24
DK1858920T3 (en) 2016-02-29
CY1117732T1 (el) 2017-05-17
MX2007010043A (en) 2008-08-29
US20160244489A1 (en) 2016-08-25
EP2351772A1 (en) 2011-08-03
CY1118149T1 (el) 2017-06-28
US20140356389A1 (en) 2014-12-04
LT2351772T (lt) 2016-10-10
NZ561042A (en) 2011-03-31
IL185359A0 (en) 2008-02-09
ES2569654T3 (es) 2016-05-12
PL1858920T3 (pl) 2016-12-30
HUE030881T2 (en) 2017-06-28
US9334313B2 (en) 2016-05-10
US10035826B2 (en) 2018-07-31
WO2006089264A3 (en) 2007-04-05
JP2012152228A (ja) 2012-08-16
SI2351772T1 (sl) 2016-11-30
IL206012A0 (en) 2010-11-30
AU2006214064A1 (en) 2006-08-24
WO2006089264A8 (en) 2008-03-06
PT2351772T (pt) 2016-09-22
ES2595363T3 (es) 2016-12-29
US20080193470A1 (en) 2008-08-14
AU2006214064B2 (en) 2012-04-26
NZ597769A (en) 2013-09-27
US8758764B2 (en) 2014-06-24
EP1858920B1 (en) 2016-02-03
CA2601924A1 (en) 2006-08-24
MX306302B (en) 2012-12-19
JP2008529558A (ja) 2008-08-07
DK2351772T3 (en) 2016-09-05
HUE027400T2 (en) 2016-10-28
US20180298064A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
SG160329A1 (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
PT1928882E (pt) (s)-n-metilnaltrexona, processo para a sua síntese e sua utilização farmacêutica
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2007003898A8 (en) Process for attaching effector molecules to proteins
WO2008036392A3 (en) Genetically programmed expression of selectively sulfated proteins in eubacteria
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
EP2251035A3 (en) New virulence factors of Streptococcus pneumoniae
WO2008045015A8 (en) Imino and amino sugar purification
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
WO2004007664A3 (en) Nucleic acid vectors
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2008021367A3 (en) Moenomycin biosynthesis-related compositions and methods of use thereof
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
NO20082989L (no) Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2008083191A3 (en) Radiofluorination methods
WO2008127450A8 (en) Linear expression cassette vaccines
WO2006010805A3 (fr) Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila
WO2007028259A3 (en) Antigens for vaccination against and detection of mycoplasma suis
WO2007034183A3 (en) Process for the preparation of 4-aminopyrazole derivatives
WO2007054968A3 (en) Novel pharmaceutical compositions of clopidogrel mesylate
WO2006111285A3 (de) Imino-oxazolidine und ihre verwendung als antikoagulantien